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Abstract: Multiparametric MRI incorporating T2-weighted, diffusion-
weighted, and dynamic contrast material–enhanced sequences is currently
used for detection and localization of clinically important prostate cancer
(PCa). The 68Ga-labeled PET tracer targeting the prostate-specific mem-
brane antigen (PSMA, 68Ga-PSMA-11) is a promising diagnostic approach
for staging and restating PCa. Recent studies suggest that 68Ga-PSMA could
also be used for primary PCa detection and localization. We report a case of
a 68Ga-PSMA PET/MR-positive lesion of the peripheral zone in a 73-year-
old man with a negative preceding multiparametric MRI. Radical prostatec-
tomy and subsequent histopathologic examination confirmed a Gleason
4 + 4 PCa.
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FIGURE 1. Multiparametric MRI (mpMRI). A 73-year-old man with newly diagnosed surge of prostate-specific antigen
from 2.15 to 2.85 ng/mL. Transverse T2-weighted images (A) show slight hypointense signal in the peripheral zone basal
posterior on both sides. Prostate Imaging Reporting and Data System (PI-RADS) version 21 using information from
diffusion-weighted imaging (B) apparent diffusion coefficient (ADC) map (shown in C) and dynamic contrast-enhanced
imaging (not shown) resulted in a PI-RADS scores of 2 for the right and left basal sextant. However, rectal gas limited image
interpretation, especially because of artifacts in the diffusion-weighted images.
FIGURE 2. 68Ga prostate-specific membrane antigen (PSMA) PET/MRI scan 1month after a template biopsy and 8months after
the initial mpMRI of the prostate. Template biopsy revealed an adenocarcinoma of the prostate with Gleason score (GS)
4 + 4 = 8 in 2 of 33 cores. Prostate-specific antigen level was 3.82 ng/mL at scan time of the PET/MRI. Transverse T2-weighted
images (A) show diffuse hypointense signal in the peripheral zone basal posterior on both sides, diffusion-weighted imaging
(B) and ADC map shown in (C) do not demonstrate restricted diffusion. Axial (D) and coronal fused (E) 68Ga-PSMA PET/MRI
scans show a single PSMA-positive prostatic lesion of 6  6  6 mm in the left basal sextant with an SUVmax of 6.9. There was
no evidence of local or distant metastasis. T1-weighted image (F) shows several postbioptic changes that are reported
not to influence the PET.2
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FIGURE 3. Reconstructed histopathological slices of the corresponding prostate after radical prostatectomy and pelvic lymph
node (LN) dissection. H&E-stained (A) and PSMA-stained slice (B) show a GS 4 + 4 prostate cancer (PCa) of the left basal
sextant that match the PSMA-positive lesion. Note the mainly membranous staining in PCa, whereas the benign tissue (NO)
shows a predominant cytoplasmic staining3 (insets). No positive LNwas found in the LN dissection specimen. Despitemultiple
publications showing a good correlation betweenmpMRI with ADC and higher GS PCa,4–8 cases with clinically relevant PCa and
false-negative mpMRI have been reported.9,10 More recently, cases with clinically relevant PCa, false-negative mpMRI, and
true-positive PSMA PET have been reported.11,12 PSMA PET/MR has been described as a potential tool for staging of high-risk
PCa with improved sensitivity for LN and distant metastasis.2 In our case, PSMA PET/MR clearly delineated the highly
aggressive tumor, not detected on mpMRI and therefore improved the sensitivity for the local tumor. Furthermore, LN and
distant metastasis could be ruled out. PSMA PET/MRmight be used as a “trouble shooter” in selected cases with discrepancies
between mpMRI and biopsy results.
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